Similar articles

• Changing concepts of Alzheimer disease.

  McKhann GM. McKhann GM. JAMA. 2011 Jun 15;305(23):2458-9. doi: 10.1001/jama.2011.810. JAMA. 2011. PMID: 21673298 No abstract available.
• Are CSF biomarkers ready for prime time as diagnostics for Alzheimer disease? Interview by Rebecca Voelker.

  Holtzman DM. Holtzman DM. JAMA. 2010 Nov 3;304(17):1887. doi: 10.1001/jama.2010.1587. JAMA. 2010. PMID: 21045090 No abstract available.
• Preclinical biomarkers in Alzheimer disease: a sum greater than the parts.

  Resnick SM. Resnick SM. JAMA Neurol. 2014 Nov;71(11):1357-8. doi: 10.1001/jamaneurol.2014.2462. JAMA Neurol. 2014. PMID: 25221849 Free PMC article. No abstract available.
• Predicting Alzheimer dementia in mild cognitive impairment patients. Are biomarkers useful?

  Borroni B, Di Luca M, Padovani A. Borroni B, et al. Eur J Pharmacol. 2006 Sep 1;545(1):73-80. doi: 10.1016/j.ejphar.2006.06.023. Epub 2006 Jun 16. Eur J Pharmacol. 2006. PMID: 16831417 Review.
• [Biomarkers in cerebrospinal fluid and blood in memory complaints].

  Zetterberg H, Andreasen N, Blennow K. Zetterberg H, et al. Lakartidningen. 2009 May 13-19;106(20):1386-9. Lakartidningen. 2009. PMID: 19585836 Review. Swedish. No abstract available.